Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease
- 1 July 2004
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 2 (7), 542-553
- https://doi.org/10.1016/s1542-3565(04)00238-1
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexateArthritis & Rheumatism, 2004
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Magic bullets hit the targetNature, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid DiseaseImmunological Reviews, 1995
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestineClinical and Experimental Immunology, 1990
- The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infectionCell, 1989
- Immunogenicity of recombinant DNA human insulinDiabetologia, 1983